HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer

Purpose: To investigate the implications of the introduction of two hormonal therapies, abiraterone acetate + prednisone (AA+P) and enzalutamide (ENZA), for the treatment of naïve patients with metastatic castration-resistant prostate cancer (mCRPC) in the Italian setting. Methods: In 2017–2018, a H...

Descripción completa

Detalles Bibliográficos
Autores principales: Bretoni, Alberto, Ferrario, Lucrezia, Foglia, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489625/
https://www.ncbi.nlm.nih.gov/pubmed/31114269
http://dx.doi.org/10.2147/CEOR.S189436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489625/
https://www.ncbi.nlm.nih.gov/pubmed/31114269
http://dx.doi.org/10.2147/CEOR.S189436

Ejemplares similares